HDFC Pharma and Healthcare Fund vs Invesco India Consumption Fund
Direct Plan, Growth option · Data as on 30-10-2026
HDFC Pharma and Healthcare Fund is a Thematic fund and Invesco India Consumption Fund is a Thematic fund. In the year to 30-10-2026, HDFC Pharma and Healthcare Fund (Direct) returned 23.1% and Invesco India Consumption Fund (Direct) returned 7.1%. HDFC Pharma and Healthcare Fund charges 1.05% a year and Invesco India Consumption Fund 1.18% (Direct plans). Their portfolios overlap 8.5%: they hold 5 of the same securities.
HDFC Pharma and Healthcare Fund
Thematic
- 1 year return
- 23.1%
- Expense ratio
- 1.05%
- NAV
- ₹21.95
Invesco India Consumption Fund
Thematic
- 1 year return
- 7.1%
- Expense ratio
- 1.18%
- NAV
- ₹10.73
Which is better, HDFC Pharma and Healthcare or Invesco India Consumption? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- HDFC Pharma and Healthcare returned more over 1 year: 23.1% against 7.1%.
- HDFC Pharma and Healthcare costs less: 1.05% a year against 1.18% (Direct plans).
- HDFC Pharma and Healthcare fell less in its worst fall since 29-10-2025: −9.8% against −15.6%.
- HDFC Pharma and Healthcare is the larger fund: ₹3,501 Cr against ₹590 Cr.
- Their portfolios overlap 8.5%: 5 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | HDFC Pharma and Healthcare Fund | Invesco India Consumption Fund |
|---|---|---|
| Fund house | HDFC Mutual Fund | Invesco Mutual Fund |
| Category | Thematic | Thematic |
| AUM | ₹3,501 Cr (30-09-2026) | ₹590 Cr (30-09-2026) |
| NAV | ₹21.95 (Direct) | ₹10.73 (Direct) |
| Expense ratio (Direct) | 1.05% | 1.18% |
| Expense ratio (Regular) | 2.13% | 2.67% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | Nifty India Consumption TRI |
| Launch date | 04-10-2023 | 28-10-2025 |
| Minimum investment | ₹100 | Not available |
| Lock in | None | None |
| Fund managers | Nikhil Mathur, Gopal Agrawal, Bhagyesh Kagalkar | Manish Poddar |
| Exit load | In respect of each purchase/switch-in of units, an Exit load of 1% is payable if units are redeemed /switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched out after 30 days from the date of allotment. | Exit load of 0.50%, if redeemed within 3 months. |
HDFC Pharma and Healthcare vs Invesco India Consumption: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund (Direct) | +0.04% | +0.83% | +16.68% | +23.12% | +30.53% | -- | -- |
| Invesco India Consumption Fund (Direct) | −1.56% | −0.37% | +13.31% | +7.09% | -- | -- | -- |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | -- | -- | -- |
Category average: the average of the 235 Thematic funds, same plan type.
HDFC Pharma and Healthcare vs Invesco India Consumption: Year-wise Returns
| Year | HDFC Pharma and HealthcareHDFC Pharma and Healthcare | Invesco India ConsumptionInvesco India Consumption |
|---|---|---|
| 2026to date | +23.99% | +9.94% |
| 2025 | +2.42% | -- |
| 2024 | +52.22% | -- |
HDFC Pharma and Healthcare vs Invesco India Consumption: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of HDFC Pharma and Healthcare Fund
HDFC Pharma and Healthcare vs Invesco India Consumption: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 01-10-2025 to 30-10-2026: 13 instalments, ₹1,30,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| HDFC Pharma and HealthcareHDFC Pharma and Healthcare Fund (Direct) | ₹1,30,000 | ₹1,49,961 | ₹19,961 | 27.4% |
| Invesco India ConsumptionInvesco India Consumption Fund (Direct) | ₹1,30,000 | ₹1,41,059 | ₹11,059 | 15.2% |
HDFC Pharma and HealthcareHDFC Pharma and Healthcare Fund (Direct)
Invesco India ConsumptionInvesco India Consumption Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
HDFC Pharma and Healthcare vs Invesco India Consumption: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | HDFC Pharma and Healthcare Fund (Direct) | Invesco India Consumption Fund (Direct) |
|---|---|---|
| Return (CAGR) | +23.12% | +7.09% |
| Standard deviation | 13.67% | 16.32% |
| Sharpe ratio | 1.31 | 0.11 |
| Sortino ratio | 1.93 | 0.16 |
| Maximum drawdown | −9.8% (23-10-2026) | −15.6% (23-03-2026) |
| Beta | 0.95 | 0.95 |
| Alpha | +11.09% | +16.93% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | HDFC Pharma and Healthcare Fund (Direct) | Invesco India Consumption Fund (Direct) |
|---|---|---|
| Return (CAGR) | +29.32% | +7.07% |
| Standard deviation | 13.98% | 16.30% |
| Sharpe ratio | 1.66 | 0.11 |
| Sortino ratio | 2.38 | 0.16 |
| Maximum drawdown | −14.9% (28-02-2025) | −15.6% (23-03-2026) |
| Beta | 0.95 | 0.95 |
| Alpha | +8.51% | +17.38% |
From daily NAVs, 04-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
HDFC Pharma and Healthcare Fund (Direct)
Invesco India Consumption Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund (Direct) | −9.8% | 21-09-2026 | 23-10-2026 | Not yet | -- | −4.1% |
| Invesco India Consumption Fund (Direct) | −15.6% | 30-10-2025 | 23-03-2026 | 15-06-2026 | 3 months | −5.0% |
| BSE Healthcare TRI | −9.9% | 23-09-2026 | 23-10-2026 | Not yet | -- | −3.8% |
From daily values since 29-10-2025, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
HDFC Pharma and Healthcare Fund (Direct)
Invesco India Consumption Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| HDFC Pharma and Healthcare Fund (Direct) | 122% | 83% | 2.41% |
| Invesco India Consumption Fund (Direct) | 98% | 122% | 9.72% |
From month-end values since 29-10-2025. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
HDFC Pharma and Healthcare vs Invesco India Consumption: Portfolio Overlap
From each fund's latest monthly portfolio: HDFC Pharma and Healthcare Fund, September 2026; Invesco India Consumption Fund, September 2026
Holdings in common
- Overlap
- 8.5%
- Held by both
- 5
- Only in HDFC Pharma and Healthcare
- 33
- Only in Invesco India Consumption
- 39
| Security | % of HDFC Pharma and Healthcare | % of Invesco India Consumption |
|---|---|---|
| Max Healthcare Institute Limited | 3.61% | 2.20% |
| Krishna Institute Of Medical Sciences Limited | 2.10% | 3.03% |
| Torrent Pharmaceuticals Ltd. | 3.65% | 1.90% |
| Global Health Limited | 2.72% | 1.21% |
| CORONA REMEDIES LIMITED | 1.04% | 2.74% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 8.5% means 8.5% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in HDFC Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Divis Laboratories Ltd. | 9.39% |
| Sun Pharmaceutical Industries Ltd. | 8.28% |
| Alkem Laboratories Ltd. | 4.64% |
| Cipla Ltd. | 4.15% |
| Apollo Hospitals Enterprise Ltd. | 3.69% |
Largest holdings only in Invesco India Consumption Fund
| Security | % of fund |
|---|---|
| Eternal Limited | 6.16% |
| Milky Mist Dairy Food Limited | 4.14% |
| TVS Motor Company Limited | 3.45% |
| Mahindra & Mahindra Limited | 3.41% |
| Bharti Airtel Limited | 3.39% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | HDFC Pharma and Healthcare | Invesco India Consumption |
|---|---|---|
| Equity | 96.8% | 99.4% |
| Debt | 0.0% | 0.0% |
| Cash and others | 3.2% | 0.6% |
Market cap of stocks
| Market cap | HDFC Pharma and Healthcare | Invesco India Consumption |
|---|---|---|
| Large Cap | 29.2% | 34.8% |
| Mid Cap | 30.1% | 12.8% |
| Small Cap | 32.5% | 39.8% |
| Not on AMFI's list | 5.0% | 12.0% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | HDFC Pharma and Healthcare | Invesco India Consumption |
|---|---|---|
| Pharmaceuticals & Biotechnology | 71.3% | 4.6% |
| Healthcare Services | 22.1% | 8.8% |
| Retailing | 1.0% | 18.0% |
| Auto Components | 0.0% | 14.6% |
| Automobiles | 0.0% | 10.7% |
| Consumer Durables | 0.0% | 9.7% |
| Transport Services | 0.0% | 5.2% |
| Healthcare Equipment & Supplies | 2.4% | 0.0% |
The six largest sectors of each fund's stocks, % of the fund.
HDFC Pharma and Healthcare vs Invesco India Consumption: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | HDFC Pharma and Healthcare Fund | Invesco India Consumption Fund |
|---|---|---|
| Total expense ratio (Direct) | 1.05% | 1.18% |
| Base expense ratio (Direct) | 0.71% | 0.76% |
| Total expense ratio (Regular) | 2.13% | 2.67% |
| Base expense ratio (Regular) | 1.65% | 2.08% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare HDFC Pharma and Healthcare with
HDFC Pharma and Healthcare Fund vs Invesco India Consumption Fund: Frequently Asked Questions
What is the difference between HDFC Pharma and Healthcare Fund and Invesco India Consumption Fund?
HDFC Pharma and Healthcare Fund is a Thematic fund, Invesco India Consumption Fund is a Thematic fund, run by HDFC Mutual Fund and Invesco Mutual Fund. Their portfolios overlap 8.5%. HDFC Pharma and Healthcare Fund charges 1.05% a year and Invesco India Consumption Fund 1.18%.
Which has given higher returns, HDFC Pharma and Healthcare Fund or Invesco India Consumption Fund?
Over 1 year: HDFC Pharma and Healthcare Fund +23.12%, Invesco India Consumption Fund +7.09%. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, HDFC Pharma and Healthcare Fund or Invesco India Consumption Fund?
HDFC Pharma and Healthcare Fund charges less: 1.05% a year against 1.18%. These are the Direct plans' total expense ratios reported to AMFI.
How much do HDFC Pharma and Healthcare Fund and Invesco India Consumption Fund overlap?
8.5%. They hold 5 of the same securities, the largest shared ones being MAXHEALTH, KIMS, TORNTPHARM. From each fund's latest monthly portfolio.
Which is riskier, HDFC Pharma and Healthcare Fund or Invesco India Consumption Fund?
On SEBI's riskometer, HDFC Pharma and Healthcare Fund is rated Very High and Invesco India Consumption Fund Very High. Over 1 years, the standard deviation of daily returns was 13.67% and 16.32% a year.
Can I invest in both HDFC Pharma and Healthcare Fund and Invesco India Consumption Fund?
Yes. 8.5% of each fund's money sits in the same holdings, so the two hold mostly different investments.
Who manages HDFC Pharma and Healthcare Fund and Invesco India Consumption Fund?
HDFC Pharma and Healthcare Fund: Nikhil Mathur, Gopal Agrawal, Bhagyesh Kagalkar. Invesco India Consumption Fund: Manish Poddar.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.